NasdaqGM:WVE

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces of novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. More Details


Snowflake Analysis

Flawless balance sheet with limited growth.


Similar Companies

Share Price & News

How has Wave Life Sciences's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: WVE is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: WVE's weekly volatility (10%) has been stable over the past year.


Market Performance


7 Day Return

-1.1%

WVE

-1.4%

US Pharmaceuticals

-4.0%

US Market


1 Year Return

14.6%

WVE

14.8%

US Pharmaceuticals

46.6%

US Market

Return vs Industry: WVE matched the US Pharmaceuticals industry which returned 14.8% over the past year.

Return vs Market: WVE underperformed the US Market which returned 46.6% over the past year.


Shareholder returns

WVEIndustryMarket
7 Day-1.1%-1.4%-4.0%
30 Day-14.2%-3.1%-4.1%
90 Day12.1%0.9%3.3%
1 Year14.6%14.6%18.7%14.8%49.8%46.6%
3 Year-77.9%-77.9%24.5%14.8%47.8%38.4%
5 Year-41.5%-41.5%45.4%28.3%116.6%92.6%

Long-Term Price Volatility Vs. Market

How volatile is Wave Life Sciences's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Wave Life Sciences undervalued compared to its fair value and its price relative to the market?

5.85x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate WVE's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate WVE's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: WVE is unprofitable, so we can't compare its PE Ratio to the US Pharmaceuticals industry average.

PE vs Market: WVE is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate WVE's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: WVE is overvalued based on its PB Ratio (5.8x) compared to the US Pharmaceuticals industry average (4.1x).


Next Steps

Future Growth

How is Wave Life Sciences forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?

12.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: WVE is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: WVE is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: WVE is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: WVE's revenue (37.3% per year) is forecast to grow faster than the US market (9.9% per year).

High Growth Revenue: WVE's revenue (37.3% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if WVE's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Wave Life Sciences performed over the past 5 years?

-31.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: WVE is currently unprofitable.

Growing Profit Margin: WVE is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: WVE is unprofitable, and losses have increased over the past 5 years at a rate of 31.4% per year.

Accelerating Growth: Unable to compare WVE's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: WVE is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-3.5%).


Return on Equity

High ROE: WVE has a negative Return on Equity (-165.37%), as it is currently unprofitable.


Next Steps

Financial Health

How is Wave Life Sciences's financial position?


Financial Position Analysis

Short Term Liabilities: WVE's short term assets ($230.0M) exceed its short term liabilities ($121.0M).

Long Term Liabilities: WVE's short term assets ($230.0M) exceed its long term liabilities ($67.5M).


Debt to Equity History and Analysis

Debt Level: WVE is debt free.

Reducing Debt: WVE has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: WVE has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: WVE has sufficient cash runway for 1.8 years if free cash flow continues to reduce at historical rates of 38.7% each year.


Next Steps

Dividend

What is Wave Life Sciences's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate WVE's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate WVE's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if WVE's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if WVE's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of WVE's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.5yrs

Average management tenure


CEO

Paul Bolno (46 yo)

7.25yrs

Tenure

US$3,581,526

Compensation

Dr. Paul B. Bolno, M.D., MBA serves as Director at SQZ Biotechnologies Company since June 2020. He has been the Chief Executive Officer and President of WAVE Life Sciences Ltd. since December 2013. Prior t...


CEO Compensation Analysis

Compensation vs Market: Paul's total compensation ($USD3.58M) is above average for companies of similar size in the US market ($USD1.48M).

Compensation vs Earnings: Paul's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Paul Bolno
President7.25yrsUS$3.58m0.44%
$ 2.2m
Chandra Vargeese
Chief Technology Officer0.75yrUS$1.24m0.048%
$ 233.5k
Michael A. Panzara
Chief Medical Officer and Head of Therapeutics Discovery & Development2.25yrsUS$1.27m0.050%
$ 243.5k
Kyle Moran
CFO & Principal Accounting Officer0.25yrno data0.033%
$ 159.8k
Kate Rausch
Head of Investor Relations1.92yrsno datano data
Linda Rockett
General Counsel4.83yrsno datano data
Christopher Francis
Senior VP of Corporate Development & Head of Emerging Areas4.17yrsUS$1.68m0.038%
$ 183.1k
Jonathan Rosin
Chief Human Resources Officer0.25yrno datano data
Jose Juves
Senior Vice President of Corporate Affairs & Patient Advocacy1.17yrsno datano data
Kenneth Rhodes
Senior Vice President of Therapeutics Discovery0.83yrno datano data
Michael Byrne
Director of In Vivo Biology and Ophthalmologyno datano datano data
Graham Morrell
Investor Relations Officerno datano datano data

1.5yrs

Average Tenure

49yo

Average Age

Experienced Management: WVE's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Paul Bolno
President7.25yrsUS$3.58m0.44%
$ 2.2m
Gregory Verdine
Director7.67yrsUS$293.16k0.061%
$ 297.6k
Mark H. Corrigan
Independent Director1.5yrsUS$259.09kno data
Christian Henry
Independent Director4.33yrsUS$206.11k0%
$ 0
Adrian Rawcliffe
Independent Director4.08yrsUS$150.88k0%
$ 0
Peter Kolchinsky
Independent Director6.17yrsUS$151.60k0%
$ 0
Ken Takanashi
Independent Director8.67yrsUS$151.33k0%
$ 0
Heidi Wagner
Independent Director1.5yrsUS$258.28kno data
Aik Tan
Independent Director0.58yrno datano data

4.3yrs

Average Tenure

52yo

Average Age

Experienced Board: WVE's board of directors are considered experienced (4.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 41.9%.


Top Shareholders

Company Information

Wave Life Sciences Ltd.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Wave Life Sciences Ltd.
  • Ticker: WVE
  • Exchange: NasdaqGM
  • Founded: 2012
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$486.054m
  • Shares outstanding: 49.00m
  • Website: https://www.wavelifesciences.com

Number of Employees


Location

  • Wave Life Sciences Ltd.
  • Marina One East Tower
  • No. 12-00, 7 Straits View
  • Singapore
  • 18936
  • Singapore

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
WVENasdaqGM (Nasdaq Global Market)YesOrdinary SharesUSUSDNov 2015
1U5DB (Deutsche Boerse AG)YesOrdinary SharesDEEURNov 2015

Biography

Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces of novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. The compan...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/03/09 00:34
End of Day Share Price2021/03/08 00:00
Earnings2020/12/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.